AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 283 min read$CNMD

Sales fell 0.7%, but grew 6.7% after currency shifts and exited product lines were excluded.

CONMED reported Q3 2026 sales down 0.7% YoY but up 6.7% excluding currency shifts and exited product lines. Domestic sales fell 11.0% as reported but rose 0.8% organically. International sales increased 13.1% as reported. GAAP EPS rose 613.7% to $1.72, while adjusted EPS dropped 3.2% to $3.10. The company updated its full-year guidance, reflecting strong Q3 performance and market focus on key product platforms.

Original reporting
stocktitan.net
Published Oct 28, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CNMD
Neutral
high confidence
Mentioned
$CNMD
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CNMDNeutralMed
01

Why it matters

The mixed earnings picture may cause short‑term price pressure, but long‑term growth themes remain intact.

02

Market read

First‑time disclosure of Q3 results and guidance for a mid‑cap med‑tech firm; relevant for traders focused on healthcare equipment equities.

03

What to watch

Excluding GI product exits, the underlying business shows strong momentum; the guidance bump may be understated.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

CONMED released its Q3 2026 results, highlighting a 0.7% YoY sales decline but 6.7% organic growth after strategic exits, and provided updated full‑year guidance.

Company-level read

Ticker impact

$CNMDNeutralHigh confidence
Context

Q3 2026 sales fell 0.7% YoY but net sales rose 6.7% organic after GI product exits; company updated full‑year 2026 guidance.

Expected impact

likely slight downside as market prices in the sales dip, offset by organic growth narrative

Evidence & confidence

The earnings release presents new numbers and guidance; investors will weigh the mixed sales picture against growth drivers.

Market effects

Sector

Healthcare equipment sector sees mixed signals from CONMED's organic growth versus headline sales decline.

Regional

U.S. med‑tech stocks may experience modest volatility following the report.

Global

Limited; impact confined to U.S. and international investors tracking med‑tech earnings.

Counterpoint

What could challenge this read

The organic growth and new product launches could outweigh the headline sales dip, offering a buying opportunity.

Key entities

  • Executive
    Patrick J. Beyer

    President and CEO of CONMED, provided commentary on results.

Read at source← All news

StoryCONMED reports Q3 2026 results and raises FY 2026 adjusted EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$CNMDMed

Conmed Corp (CNMD) Q3 2026 Earnings Call Highlights: Solid Organic Growth Offset

Conmed Corp (CNMD) reported Q3 2026 earnings with global general surgery up 6.4% and orthopedics up 7.2%. U.S. general surgery grew 2%, while U.S. orthopedics declined slightly. CEO Pat Beyer highlighted strong performance in AirSeal and direct smoke evacuation, but noted variability in OEM business. CFO John Gallagher adjusted the organic growth range to 5.5% due to international performance. AirSeal grew in high single-digit to low double-digit range.

finance.yahoo.com6 min
OCT 29
$CNMDHighAI 8/10

CONMED Q3 Earnings Call Highlights

CONMED reported Q3 organic revenue growth of 7.2% in orthopedic surgery, driven by international demand and BioBrace. Adjusted gross margin increased to 56.4%. The company updated its 2026 outlook, narrowing revenue growth to 5%-5.5% and raising adjusted EPS guidance to $4.54-$4.61. CONMED repurchased 1.2 million shares and expects to allocate $62 million to buybacks for the year.

finance.yahoo.com3 min
OCT 29
$CNMDMed

CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

finance.yahoo.com3 min
OCT 28
$CNMDMedAI 8/10

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).

finance.yahoo.com2 min
OCT 28
$CNMDHighAI 8/10

CONMED (NYSE:CNMD) posts Q3 2026 sales in line with estimates

CONMED (CNMD) reported Q3 2026 revenue of $335.6M, flat year-on-year but in line with estimates. Adjusted EPS of $1.04 beat estimates by 3.7%. The company reconfirmed its full-year revenue guidance of $1.36B and slightly raised its EPS guidance to $4.58. Operating margin decreased to 11.1% from 3.5% year-on-year. Long-term revenue growth has slowed, with a 6.7% CAGR over five years.

finance.yahoo.com2 min